Online citations, reference lists, and bibliographies.
← Back to Search

Does A Targeting Ligand Influence Nanoparticle Tumor Localization Or Uptake?

K. Pirollo, E. Chang
Published 2008 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Inclusion of a tumor-targeting molecule in nanosized delivery systems increases their in vivo efficacy. However, the biodistribution and pharmacokinetics of the uptake of such particles have not yet been well addressed. Several recent papers have suggested that tumor-targeting ligands function primarily to increase intracellular uptake of the nanocomplex and do not influence tumor localization. However, other reports indicate that they do play a role in the accumulation in the tumor. One difference might be the presence or absence of poly-[ethylene glycol] (PEG) in the complex and its impact on the enhanced permeability and retention (EPR) effect. Further studies are clearly needed to more fully elucidate the influence of composition on tumor-targeted, systemic delivery of nanoparticles.
This paper references
10.1016/J.BIOMATERIALS.2006.09.047
Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
J. Cheng (2007)
10.1016/J.IJPHARM.2005.10.010
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.
Donald E. Owens (2006)
10.1016/J.DRUDIS.2006.07.005
Exploiting the enhanced permeability and retention effect for tumor targeting.
A. Iyer (2006)
10.1038/SJ.MT.6300176
Cellular dynamics of EGF receptor-targeted synthetic viruses.
K. D. de Bruin (2007)
10.1016/S1470-2045(07)70274-7
Non-[18F]FDG PET in clinical oncology.
A. Groves (2007)
10.1016/S1567-5769(02)00271-0
Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.
H. Maeda (2003)
10.1089/HUM.2006.17.1062
Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer.
M. Meyer (2006)
10.1002/JPS.20457
Folate receptor-mediated drug targeting: from therapeutics to diagnostics.
A. Hilgenbrink (2005)
10.1038/sj.gt.3302304
A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene
W. Yu (2004)
Monitoring cancer treatment with PET/CT: does it make a difference?
W. Weber (2007)
10.1073/pnas.0707461104
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
D. Bartlett (2007)
10.2174/187152006778699121
Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer.
T. Allen (2006)
10.1002/0471234303.CH3
Immunoliposomes: A Targeted Delivery Tool for Cancer Treatment
K. Pirollo (2003)
10.1007/s11095-006-9662-5
Long Circulating Poly(Ethylene Glycol)-Decorated Lipid Nanocapsules Deliver Docetaxel to Solid Tumors
M. Khalid (2006)
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
G. Sundaresan (2003)
10.1261/RNA.459807
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
D. De Paula (2007)
10.1089/10430349950016357
Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts.
L. Xu (1999)
10.2174/138161206779026272
Exploiting EPR in polymer drug conjugate delivery for tumor targeting.
Sweta Modi (2006)
10.1016/J.JCONREL.2006.04.009
Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability.
C. Dass (2006)
10.1080/08982100600848769
Pros and Cons of the Liposome Platform in Cancer Drug Targeting
A. Gabizon (2006)
10.1007/BF03401962
Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv
L. Xu (2001)
10.1016/S0065-2571(00)00013-3
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.
H. Maeda (2001)
10.1016/S1359-6446(05)03575-0
PEGylation, successful approach to drug delivery.
F. Veronese (2005)
10.4161/cbt.3.7.918
Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles
S. Pun (2004)
10.1089/HUM.2006.17.117
Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery.
K. Pirollo (2006)
10.2967/jnumed.107.045302
In Vivo Imaging of 64Cu-Labeled Polymer Nanoparticles Targeted to the Lung Endothelium
R. Rossin (2008)
10.1038/sj.gt.3302838
Gene therapy progress and prospects: non-viral gene therapy by systemic delivery
S-D Li (2006)
10.2174/187152007781668706
Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers.
E. Garanger (2007)
Vector Targeting for Therapeutic Gene Delivery
D. Curiel (2002)
10.1158/1535-7163.MCT-07-0615
Antitumor activity of an epithelial cell adhesion molecule–targeted nanovesicular drug delivery system
Sajid. Hussain (2007)
10.1073/PNAS.150228297
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.
A. Wu (2000)
10.1158/0008-5472.CAN-05-4328
The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas.
Yue Cao (2006)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
Y. Matsumura (1986)
10.1078/0939-3889-00288
Recent developments and future trends in nuclear medicine instrumentation.
H. Zaidi (2006)
Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.
L. Xu (2002)
10.1093/NAR/GNH049
Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide.
Wei Yu (2004)
10.1016/J.CLIM.2006.06.010
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer.
T. R. Daniels (2006)
10.1016/J.EJPS.2005.08.002
In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
Chao Fang (2006)
10.1158/0008-5472.CAN-06-4535
Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
K. Pirollo (2007)
10.1038/sj.gt.3301351
Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application
R. Kircheis (2001)
10.1158/0008-5472.CAN-05-4199
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
D. Kirpotin (2006)
10.1080/10717540600814402
Pharmacokinetic Consequences of Pegylation
M. Hamidi (2006)



This paper is referenced by
10.1039/C6TB01743F
Tumor therapy: targeted drug delivery systems.
L. Dai (2016)
10.3109/1061186X.2013.805336
Effect of surface charge and ligand organization on the specific cell-uptake of uPAR-targeted nanoparticles
M. Wang (2013)
Newer Developments in the Nanoparticles for Cancer Treatment.
N. Patel (2014)
10.1039/c9cs00309f
Nanoparticles' interactions with vasculature in diseases.
J. K. Tee (2019)
10.1016/j.jconrel.2020.07.043
Immune cells as tumor drug delivery vehicles.
F. Combes (2020)
10.1002/anie.201610819
From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers.
Sarah R MacEwan (2017)
10.1063/1.5052455
Physics in nanomedicine: Phenomena governing the in vivo performance of nanoparticles
Lucas A Lane (2020)
10.1039/c2cs15344k
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.
Nazila Kamaly (2012)
Chapter 2 Improved Targeting of Cancers with Nanotherapeutics
Christian Foster (2018)
10.1016/j.biomaterials.2014.08.032
One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles.
Chien-Han Kao (2014)
10.1016/j.jconrel.2009.04.010
Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels.
A. Mikhail (2009)
10.1371/journal.pone.0072938
A Liposomal Drug Platform Overrides Peptide Ligand Targeting to a Cancer Biomarker, Irrespective of Ligand Affinity or Density
B. Gray (2013)
Gold-silica quantum rattles for cancer therapy and diagnosis
Mathew Hembury (2012)
10.1007/978-1-4614-7876-8_2
Nanotechnology for Cancer Treatment: Possibilities and Limitations
Joseph W. Nichols (2013)
10.1016/j.nano.2015.07.015
Design considerations for nanotherapeutics in oncology.
T. Stylianopoulos (2015)
10.1039/C6NJ00655H
EDTA capped iron oxide nanoparticles magnetic micelles: drug delivery vehicle for treatment of chronic myeloid leukemia and T1–T2 dual contrast agent for magnetic resonance imaging
E. Shah (2016)
Enhanced Solubility and Targeted Delivery of Drugs using Cucurbit[n]uril-Type Compounds
G. Hettiarachchi (2013)
10.1002/adma.201801362
Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.
Denzil Furtado (2018)
10.1016/j.colsurfb.2018.01.035
Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor.
Shahrzad Amiri Darban (2018)
10.2147/IJN.S63717
Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy
L. Liu (2014)
10.15272/AJBPS.V4I28.427
Nanotechnology: A possible healer in drug delivery system
Moniruzzaman (2014)
10.1186/s12951-016-0172-2
NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?
Sten Friberg (2016)
10.1007/s13233-012-0059-5
pH-sensitive polymers for drug delivery
K. Huh (2012)
Title Pharmacokinetic considerations for targeted drug delivery
F. Yamashita (2016)
10.1016/B978-0-323-46144-3.00006-4
Progress of nanoparticles research in cancer therapy and diagnosis
I. Negut (2017)
10.3923/TMR.2012.34.42
Nanotechnology: A Tool to Enhance Therapeutic Values of Natural Plant Products
A. Kumari (2012)
LETHAL WEAPONS - Novel approaches for receptor-targeted cancer cell elimination
Emilia Peuhu (2010)
FACULTY OF PHYSICS ADAM MICKIEWICZ UNIVERSITY NANOBIOMEDICAL CENTRE DEPARTMENT OF MEDICAL PHYSICS POZNAŃ Synthesis and evaluation of superparamagnetic iron oxide nanoparticles containing doxorubicin as a potential targeted drug delivery system
Magdalena Hałupka (2015)
10.1039/C4TB00321G
Reduction breakable cholesteryl pullulan nanoparticles for targeted hepatocellular carcinoma chemotherapy.
Huanan Li (2014)
10.1007/s10311-018-00841-1
Nanocarriers for drug delivery applications
M. Chamundeeswari (2018)
10.1517/17425247.2011.554818
Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems
P. Karmali (2011)
Characterizing Topology of Surface Ligands on Liposomes
S. Lee (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar